Congenital heart disease and pulmonary hypertension.

Many patients with congenital heart disease and systemic-to-pulmonary shunts develop pulmonary arterial hypertension (PAH), particularly if the cardiac defect is left unrepaired. A persistent increase in pulmonary blood flow may lead to obstructive arteriopathy and increased pulmonary vascular resistance, a condition that can lead to reversal of shunt and cyanosis (Eisenmenger syndrome). Cardiac catheterization is crucial to confirm diagnosis and facilitate treatment. Bosentan is the only medication to date to be compared with placebo in a randomized controlled trial specifically targeting congenital heart disease-associated PAH. Lung transplantation with repair of the cardiac defect or combined heart-lung transplantation is reserved for recalcitrant cases.
AuthorsVedant Gupta, Adriano R Tonelli, Richard A Krasuski
JournalHeart failure clinics (Heart Fail Clin) Vol. 8 Issue 3 Pg. 427-45 (Jul 2012) ISSN: 1551-7136 [Print] United States
PMID22748904 (Publication Type: Journal Article, Review)
CopyrightCopyright © 2012 Elsevier Inc. All rights reserved.
  • Arrhythmias, Cardiac
  • Cardiac Catheterization
  • Exercise Test
  • Exercise Tolerance
  • Heart Defects, Congenital (complications, drug therapy, pathology)
  • Hemoptysis
  • Humans
  • Hypertension, Pulmonary (drug therapy, etiology, pathology)
  • Oxygen Inhalation Therapy
  • Pulmonary Embolism
  • Risk Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: